within Pharmacolibrary.Drugs.ATC.C;

model C02CA04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 3.6666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.041,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 600,            
    Vdp             = 0.106,
    k12             = 59,
    k21             = 59
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02CA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Doxazosin is an alpha-1 adrenergic receptor antagonist primarily used to treat hypertension and benign prostatic hyperplasia (BPH) in adults. It is approved and widely used today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Li, Q, et al., &amp; Ren, L (2015). Enantioselective pharmacokinetics of doxazosin and pharmacokinetic interaction between the isomers in rats. <i>Chirality</i> 27(10) 738–744. DOI:<a href=&quot;https://doi.org/10.1002/chir.22483&quot;>10.1002/chir.22483</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26205661/&quot;>https://pubmed.ncbi.nlm.nih.gov/26205661</a></p></li><li><p>Vincent, J, et al., &amp; Reid, JL (1983). Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. <i>British journal of clinical pharmacology</i> 15(6) 719–725. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1983.tb01556.x&quot;>10.1111/j.1365-2125.1983.tb01556.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6135439/&quot;>https://pubmed.ncbi.nlm.nih.gov/6135439</a></p></li><li><p>Taylor, SH (1989). Clinical pharmacotherapeutics of doxazosin. <i>The American journal of medicine</i> 87(2A) 2S–11S. DOI:<a href=&quot;https://doi.org/10.1016/0002-9343(89)90107-1&quot;>10.1016/0002-9343(89)90107-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2569822/&quot;>https://pubmed.ncbi.nlm.nih.gov/2569822</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02CA04;
